US2023110003A1PendingUtilityA1

Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)

Assignee: VALO HEALTH INCPriority: May 9, 2011Filed: Sep 9, 2022Published: Apr 13, 2023
Est. expiryMay 9, 2031(~4.8 yrs left)· nominal 20-yr term from priority
A61P 13/12C07D 471/04C07D 513/04A61K 45/06C07D 215/48A61P 31/22A61P 19/10A61P 9/00A61K 31/4709A61P 35/02A61P 1/00A61P 3/00C07D 495/04A61K 31/497A61P 11/00A61P 25/00A61P 25/28A61K 31/5377A61P 35/00A61K 31/4545A61P 9/10A61P 19/02A61P 43/00A61K 31/4375C07D 519/00A61K 31/4365A61K 31/437A61P 3/10A61P 37/08C07D 491/048A61P 29/00A61P 17/06A61P 17/00A61P 37/02A61P 31/18A61P 11/06A61P 31/12
78
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: Formula (I)

Claims

exact text as granted — not AI-modified
1 - 28 . (canceled) 
     
     
         29 . A compound of Formula IB: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein: 
         R is an aryl, heteroaryl, C 3 -C 8  cycloalkyl, C 3 -C 8  cycloalkenyl, heterocycloalkyl, arylalkyl-, (heteroaryl)alkyl-, (C 3 -C 8  cycloalkyl)alkyl-, (C 3 -C 8  cycloalkenyl)alkyl-, (heterocycloalkyl)alkyl-, (aryloxy)alkyl-, (heteroaryloxy)alkyl-, (C 3 -C 8  cycloalkyloxy)alkyl-, (C 3 -C 8  cycloalkenyloxy)alkyl- or (heterocycloalkyloxy)alkyl-, wherein the heteroatom of each of said heteroaryl and heterocycloalkyl numbers 1, 2 or 3, and is independently selected from N, S or O, further wherein each of said aryl, heteroaryl and heterocycloalkyl may independently be either substituted or fused with an aryl or heteroaryl, still further wherein any of said aryl, heteroaryl and heterocycloalkyl is optionally substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl-, (amino)alkoxy-, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CH z F 3-z , —OCH z F 3-z , -alkyl, -alkenyl, -alkynyl, -alkoxy, hydroxyl, alkyl hydroxy, hydroxyl, alkyl hydroxy, or (alkoxyalkyl) amino-, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, -cycloalkyl, -heterocycloalkyl, -aryl, and heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O; 
         G is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, with each of said aryl, heteroaryl, heterocycloalkyl and cycloalkyl being optionally substituted with 1, 2, 3 or 4 substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl-, (amino)alkoxy-, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CH z F 3-z , —OCH z F 3-z , -alkyl, -alkenyl, -alkynyl, -alkoxy, hydroxyl, -alkyl hydroxyl, aryloxy-, (alkoxyalkyl)amino-, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, -cycloalkyl, -heterocycloalkyl, -aryl, and -heteroaryl; 
         R 3  is H, alkyl or arylalkyl-; 
         A is aryl, heteroaryl, heterocycloalkyl or C 3  to Cs cycloalkyl, with each of said aryl, heteroaryl, heterocycloalkyl and cycloalkyl being optionally substituted with 1, 2, 3 or 4 substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl-, (amino)alkoxy-, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CH z F 3-z , —OCH z F 3-z , -alkyl, -alkenyl, -alkynyl, -alkoxy, hydroxyl, -alkyl hydroxyl, aryloxy-, (alkoxyalkyl)amino-, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, -cycloalkyl, -heterocycloalkyl, -aryl, and -heteroaryl; 
         Q is C(O), S(O), S(O) 2 , or —CH 2 —C(O); 
         n is 0, 1, 2, 3, 4, 5 or 6; and 
         z is 0, 1 or 2. 
       
     
     
         30 . The compound of  claim 29 , wherein R is heteroaryl. 
     
     
         31 . The compound of  claim 29 , wherein R is (heteroaryl)alkyl. 
     
     
         32 . The compound of  claim 29 , wherein A is heterocycloalkyl. 
     
     
         33 . The compound of  claim 29 , wherein A is aryl. 
     
     
         34 . The compound of  claim 29 , wherein Q is S(O) 2 . 
     
     
         35 . The compound of  claim 29 , wherein G is optionally substituted heteroaryl. 
     
     
         36 . The compound of  claim 29 , wherein G is optionally substituted aryl. 
     
     
         37 . The compound of  claim 30 , wherein A is heterocycloalkyl. 
     
     
         38 . The compound of  claim 37 , wherein Q is S(O) 2 . 
     
     
         39 . The compound of  claim 38 , wherein G is optionally substituted heteroaryl. 
     
     
         40 . The compound of  claim 38 , wherein G is optionally substituted aryl. 
     
     
         41 . The compound of  claim 31 , wherein A is aryl. 
     
     
         42 . The compound of  claim 41 , wherein Q is S(O) 2 . 
     
     
         43 . The compound of  claim 42 , wherein G is optionally substituted heteroaryl. 
     
     
         44 . The compound of  claim 42 , wherein G is optionally substituted aryl. 
     
     
         45 . The compound of  claim 43 , wherein n is 0. 
     
     
         46 . The compound of  claim 31 , wherein R is (heteroaryl)alkyl, and alkyl is straight or branched. 
     
     
         47 . The compound of  claim 31 , wherein R is (heteroaryl)alkyl, and alkyl is cyclized. 
     
     
         48 . The compound of  claim 31 , wherein R is (pyridinyl)alkyl.

Join the waitlist — get patent alerts

Track US2023110003A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.